Trisodium Citrate

• 1. INDICATIONS AND USAGE 1.1.

2. DOSAGE AND ADMINISTRATION 2.1. To open blister package, peel cover film back 4/5 of its length. 2.2. Prepare the blood bag following your institution's standard operating procedures. 2.2.1. Materials Needed: VENOJECT II Tube Holder (code P-1316R) or equivalent VENOJECT II Multi-Sample Luer Adapter (code MN*2000T) or equivalent Evacuated blood collection tubes (glass or plastic) 2.3. Make a loose knot in the donor tubing below the "Y" and CLIKTIP (inline closure device) unless alternate methods are used to seal the tubing at the end of collection. 2.4. Temporarily clamp donor tubing between the phlebotomy needle and the "Y". 2.5. Close the White Clamp below the diversion pouch. 2.6. Assemble the luer adapter and the tube holder. 2.6.1. Connect the VENOJECT II Multi-Sample Luer Adapter to the VENOJECT II Tube Holder (or equivalent) (Fig. 1). 2.6.2. Twist and snap to remove the blue port cap at the end of the Diversion Blood Sampling Arm (Fig. 2a). 2.6.3. Insert the Holder/Luer assembly in the female luer port (Fig. 2b). 2.6.4. NOTE: Alternatively, steps 2.6.1., 2.6.2., and 2.6.3. (above) may be performed at any time during bag preparation or after the blood is collected into the diversion pouch. 2.7. Suspend the collection bag as far as possible below the donor's arm. 2.8. Apply blood pressure cuff or tourniquet to donor's arm. Disinfect site of phlebotomy according to institutional standard operating procedures. If blood pressure cuff is used, inflate to approximately 60 mmHg. 2.9. Remove the needle cover and perform phlebotomy.

5. WARNINGS AND PRECAUTIONS 5.1. Rx ONLY. 5.2. Do not use unless solutions are clear and free from particulates. 5.3. Always inspect the blood bag set for leaks before use. 5.4. Avoid excessive heat and direct sunlight. Protect from freezing. 5.5. Recommended storage conditions: Room Temperature (15-30°C/59-86°F). 5.6. It is normal to have condensation in the blister packaging. If the amount of moisture is greater than expected, check for leaks from the fluid-filled components of the blood bag set. 5.7. Use aseptic techniques. 5.8. Do not use a dielectric tube sealer to seal the tubing while the needle is connected to the donor's body unless it is approved for such a purpose. 5.9. Do not touch needle after removing the needle cover. 5.10. Assure that the White Clamp below the pouch is closed prior to initiating phlebotomy. 5.11. Do not collect donor test samples until the tubing between the "Y" and the diversion pouch is permanently sealed. 5.12. Discard the Diversion Blood Sampling Arm and phlebotomy needle/donor tubing according to institutional standard operating procedures. 5.13. The AGELESS oxygen absorber packet, (Mitsubishi Gas Chemical) contained in this package absorbs oxygen and generates heat on removal. Do not open and handle it with care. 5.14. Dispose of the AGELESS packet with the blister tray. 5.15. Do not dispose the AGELESS packet with wastes containing volatile or flammable materials. 5.16. Due to possible exposure to infectious agents in the handling of blood, take adequate precautions at all times to prevent exposure to and transmission of such agents.

1. 1Paraesthesia5,69383%
2. 2Nausea3,04944%
3. 3Dizziness2,96743%
4. 4Feeling Hot2,89642%
5. 5Pallor2,65739%
6. 6Hyperhidrosis2,31134%
7. 7Asthenia1,36920%
8. 8Thirst1,34020%
9. 9Vision Blurred1,19017%
10. 10Dysgeusia1,16517%
11. 11Chills75611%
12. 12Dyspepsia71110%
13. 13Restlessness5738.3%
14. 14Hypoaesthesia5317.7%
15. 15Muscle Spasms5167.5%

Recent PubMed references pinned to Trisodium Citrate as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Prefilled versus infused regional citrate anticoagulation during continuous renal replacement therapy on circuit lifespan: protocol for a randomised controlled trial.
  BMJ open · 2026 · Zou H, Wang F, Mali N, et al.
  PMID 41991269DOI 10.1136/bmjopen-2025-115862
• A food-grade cell dissociation agent via regulatory pre-check framework.
  PloS one · 2026 · Hatano H, Sawada M, Kitsukawa M, et al.
  PMID 41973685DOI 10.1371/journal.pone.0345921
• Comparative efficacy of low-concentration trisodium citrate and low-concentration heparin for locking central venous hemodialysis catheters: a randomized controlled study.
  Renal failure · 2026 · Pattharanitima P, Wongwatanasanti K, Tantiyavarong P, et al.
  PMID 41820022DOI 10.1080/0886022X.2026.2641842
• Regional Citrate Anticoagulation in Pediatric Patients: Dealing with Practice Points.
  Blood purification · 2026 · Ricci Z, Deep A, Goldstein SL, et al.
  PMID 41042715DOI 10.1159/000548786
• Effects of a Blend of Trisodium Citrate, Creatine Monohydrate, Leucine, and Blueberry Extract on Training-Induced Changes in Leg Extension Strength, Endurance, and Muscle Size.
  Journal of dietary supplements · 2025 · Roberts TD, Arnett JE, Ortega DG, et al.
  PMID 40537085DOI 10.1080/19390211.2025.2518408
• Perception of citric acid and citrate salt mixtures in humans.
  Chemical senses · 2025 · D'Andrea AE, Hopfer H, Hayes JE, et al.
  PMID 40481661DOI 10.1093/chemse/bjaf017
• Adverse Events in Hemodialysis Patients With Venous Catheters Locked With 30% Trisodium Citrate Versus Alternative Locking Solutions.
  Hemodialysis international. International Symposium on Home Hemodialysis · 2025 · Miller G, Feuersenger A, Ogujiofor K, et al.
  PMID 40151931DOI 10.1111/hdi.13239
• Prevalence and detection of citrate contamination in clinical laboratory.
  Clinical chemistry and laboratory medicine · 2025 · Lorde N, Gama R, Kalaria T, et al.
  PMID 39891360DOI 10.1515/cclm-2024-1389

The 10 most recently updated of 2,054 ClinicalTrials.gov registrations naming Trisodium Citrate as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
  Recruiting · Phase 2 · Phase 3 · Interventional · 189 enrolled · National Cancer Institute (NCI)
  NCT05058651updated 2026-06-12
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
  Recruiting · Phase 2 · Phase 3 · Interventional · 1,122 enrolled · National Cancer Institute (NCI)
  NCT05691478updated 2026-06-12
• A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
  Recruiting · Phase 2 · Interventional · 50 enrolled · National Cancer Institute (NCI)
  NCT06064097updated 2026-06-12
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  Recruiting · Phase 3 · Interventional · 1,210 enrolled · National Cancer Institute (NCI)
  NCT04267848updated 2026-06-12
• Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
  Recruiting · Phase 2 · Interventional · 108 enrolled · National Cancer Institute (NCI)
  NCT07281417updated 2026-06-12
• Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
  Recruiting · Phase 2 · Phase 3 · Interventional · 613 enrolled · National Cancer Institute (NCI)
  NCT01810913updated 2026-06-12
• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
  Recruiting · Phase 3 · Interventional · 478 enrolled · National Cancer Institute (NCI)
  NCT06172296updated 2026-06-12
• Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
  Completed · Phase 3 · Interventional · 40 enrolled · University Hospital, Tours
  NCT01350882updated 2026-06-12
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
  Active not recruiting · Phase 3 · Interventional · 10,273 enrolled · National Cancer Institute (NCI)
  NCT00310180updated 2026-06-11
• Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
  Recruiting · Phase 2 · Phase 3 · Interventional · 131 enrolled · National Cancer Institute (NCI)
  NCT04628767updated 2026-06-11

Frequently asked questions

What is Trisodium Citrate used for?

According to FDA labeling, Trisodium Citrate carries indications including: 1. INDICATIONS AND USAGE 1.1.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.